Perenostobart Biosimilar – Anti-ENTPD1 mAb – Research Grade from ProteoGenix; catalogue PX-TA2081; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Perenostobart Biosimilar, also known as Anti-ENTPD1 mAb, is a research grade monoclonal antibody that has shown promising results in targeting the therapeutic protein ENTPD1. In this article, we will discuss the structure, activity, and potential applications of Perenostobart Biosimilar in further detail.
Perenostobart Biosimilar is a fully humanized monoclonal antibody that is produced through recombinant DNA technology. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to its target, ENTPD1, while the constant region provides stability and effector functions.
Perenostobart Biosimilar specifically targets and binds to the protein ENTPD1, which is also known as CD39. ENTPD1 is a cell surface protein that is involved in the regulation of immune responses. It plays a crucial role in the conversion of ATP to adenosine, which has anti-inflammatory effects.
By binding to ENTPD1, Perenostobart Biosimilar blocks its activity and prevents the conversion of ATP to adenosine. This leads to an increase in the levels of ATP, which in turn activates immune cells such as T cells and natural killer cells. This activation of immune cells can help in fighting against cancer and other diseases.
ENTPD1 has been identified as a potential therapeutic target for various diseases, including cancer, autoimmune disorders, and infectious diseases. In cancer, ENTPD1 is overexpressed in tumor cells and promotes immune evasion, making it an attractive target for immunotherapy. In autoimmune disorders, ENTPD1 plays a role in suppressing the immune response, and targeting it with Perenostobart Biosimilar can help in reducing inflammation and controlling the disease. Additionally, ENTPD1 has been found to be involved in the pathogenesis of infectious diseases, making it a potential target for antiviral and antibacterial therapies.
Perenostobart Biosimilar is currently being studied in preclinical and clinical trials for its potential use in various diseases. In cancer, it is being evaluated as a potential immunotherapy for solid tumors, including melanoma, lung cancer, and ovarian cancer. It is also being studied for its potential use in combination with other cancer therapies, such as chemotherapy and checkpoint inhibitors.
In autoimmune disorders, Perenostobart Biosimilar is being investigated for its potential in treating diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis. It is also being studied for its potential in preventing transplant rejection.
In infectious diseases, Perenostobart Biosimilar is being evaluated for its potential in treating viral infections, such as hepatitis B and C, and bacterial infections, such as tuberculosis.
In summary, Perenostobart Biosimilar is a promising research grade monoclonal antibody that specifically targets ENTPD1. Its unique mechanism of action makes it a potential therapeutic option for various diseases, including cancer, autoimmune disorders, and infectious diseases. Further studies and clinical trials will help in determining the full potential of Perenostobart Biosimilar and its role in improving patient outcomes.
ProteoGenix catalogue number PX-TA2081. For research use only.
Target: Perenostobart Biosimilar – Anti-ENTPD1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Perenostobart Biosimilar – Anti-ENTPD1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
